Observed Signal · Sep 21, 2026 · funding · Source: SEC API · Impact: 4.5/5
Knorex Files Form F-1 for $50M Equity Line Amid Severe Revenue Decline
Knorex Ltd. filed a Form F-1 registration statement covering the resale of up to 156,787,119 Class A ordinary shares by selling shareholders associated with a committed equity purchase agreement of up to $50 million entered into in March 2026. The company will receive no proceeds from selling shareholder resales, though it may draw up to $50 million in gross proceeds from direct issuances under the equity facility for working capital. The filing reflects critical financial distress, showing that FY 2025 revenue contracted 44.2% year-over-year to $6.04 million due to tariffs impacting its anchor customer's end-clients. Net losses expanded to $11.55 million in FY 2025 from $5.88 million in FY 2024, resulting in a stockholders' deficit of $(6.48) million and cash reserves of just $129,104 against current liabilities of $13.33 million, prompting NYSE American continued listing deficiency notices.
The filing discloses a critical $50 million dilutive financing facility essential to mitigate substantial doubt regarding the company's going concern status and avoid NYSE American delisting.
MARKET SIGNALS
Track KNOREX Signals & Strategic Shifts
Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.
- Verified primary sources
- Automated briefings
- Instant watchlist setup
Key Takeaways & Evidence Grounding
- Files F-1 covering up to 156,787,119 Class A ordinary shares issuable under a $50 million committed equity purchase agreement.
- FY 2025 revenue fell 44.2% year-over-year to $6.04 million from $10.82 million, driven by demand contraction from its largest customer.
- FY 2025 net loss widened to $(11.55) million, with operating cash outflows of $(10.42) million leaving cash and cash equivalents of $129,104.
- Received NYSE American deficiency notice on August 21, 2026, for failing minimum stockholders' equity standards with a $(6.48) million deficit.
- Registers resale of up to 156,787,119 Class A Ordinary Shares linked to a $50.0 million equity line transaction with RK Capital Management LLC, North Commerce Parkway Capital LP, and TQP Holdings LLC.
- FY 2025 consolidated revenue declined 44.2% year-over-year to $6.04 million, primarily caused by tariff-related marketing cuts from its largest customer.
- FY 2025 net loss widened to $11.55 million from $5.88 million in FY 2024, while cash and cash equivalents stood at $129,104 as of December 31, 2025.
- Received a non-compliance notice from NYSE Regulation on August 21, 2026 due to stockholders' deficit of $(6.5) million and multi-year net losses, with a compliance plan submitted on September 20, 2026 targeting compliance by February 21, 2028.
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
KNOREX Faces Delisting as NYSE American Suspends Class A Ordinary Shares
On November 11, 2026, KNOREX Ltd. was notified by NYSE American LLC that the exchange immediately suspended trading in its Class A ordinary shares and commenced proceedings to delist the stock under Section 1003(f)(v) of the NYSE American Company Guide due to an abnormally low selling price. KNOREX intends to appeal the decision by requesting a hearing before the Listing Qualifications Panel prior to the November 18, 2026 deadline. During the appeal, shares will remain suspended from trading. To regain compliance and defend its listing, the company plans to pursue a reverse stock split, though no assurance can be given regarding a successful outcome.
6-K Financial Filing Analysis for KNOREX (2026-10-28)
Knorex Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on October 28, 2026, furnishing its unaudited condensed consolidated financial statements and operating and financial review for the six months ended June 30, 2026, and 2025. The filing serves as the company's semi-annual financial disclosure required for foreign private issuers, incorporating interim financial results in Exhibit 99.1 and accompanying management commentary in Exhibit 99.2.
6-K Financial Filing Analysis for KNOREX (2026-10-08)
On October 2, 2026, KNOREX Ltd. entered into an exchange agreement with North Commerce Parkway Capital LP and TQ Master Fund LP to exchange $3,150,000 in outstanding principal of existing senior unsecured promissory notes for new convertible promissory notes totaling $3,363,411. The new principal incorporates $129,325 in capitalized accrued interest and an $84,086 original issue discount (2.5%). The exchange was executed under Section 3(a)(9) of the Securities Act without additional cash consideration. The newly issued notes mature on January 1, 2027, and are convertible into Class A ordinary shares at a conversion price equal to the greater of 80% of the lowest 5-day VWAP or a floor price set at 20% of the NYSE American minimum price. Furthermore, the agreement mandates 100% prepayment from gross proceeds of future debt or equity financings and asset sales, creating near-term dilution risk and strict liquidity encumbrances ahead of early 2027.
WATCHLIST & BRIEFINGS
Receive future signals for KNOREX & competitors in your briefing
Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.
- Regular primary-source checks
- Structured Watchlist briefings
- Preserves current context
Market Signal Monitoring
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
Monitor KNOREX
Follow affected companies in Polaris7 with regular source checks and structured Watchlist briefings.
